Treatment Options for Early-Stage HER2+ Breast Cancer

Sarah M. Tolaney, MD, MPH, discusses the range of treatment options for early-stage HER2+ breast cancer, including subcutaneous options and investigational therapies.

EP. 1: Goals of Care for Patients with Early-Stage versus Advanced or Metastatic HER2+ Breast Cancer

May 6th 2022

Sarah M. Tolaney, MD, MPH, provides an overview of how goals of care and prognosis differ between patients with early-stage HER2+ breast cancer and advanced or metastatic HER2+ breast cancer.

EP. 2: Frontline Treatment Options for Early-Stage HER2+ Breast Cancer

May 6th 2022

Sarah M. Tolaney, MD, MPH, reviews the treatment options for patients with early-stage HER2+ breast cancer in the frontline setting.

EP. 3: Subcutaneous Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injections for Early-Stage HER2+ Breast Cancer

May 11th 2022

An expert oncologist explains the combination subcutaneous injection therapy of pertuzumab, trastuzumab, and hyaluronidase-zzxf for patients with early-stage HER2+ breast cancer.

EP. 4: Subcutaneous Treatment of Early-Stage HER2+ Breast Cancer During the COVID-19 Pandemic

May 11th 2022

Sarah M. Tolaney, MD, MPH, describes her usage of pertuzumab, trastuzumab, and hyaluronidase-zzxf subcutaneous injections in her clinical practice during the COVID-19 pandemic for patients with HER2+ breast cancer.

EP. 5: Discussing Treatment Decisions with Patients with Early-Stage HER2+ Breast Cancer

May 18th 2022

A key opinion leader explains how she discusses treatment options and trial data with patients with early stage HER2+ breast cancer.

EP. 6: The Role of Maintenance Therapy in HER2+ Breast Cancer

May 18th 2022

Dr Sarah M. Tolaney discusses whether maintenance therapy has a role in HER2+ breast cancer treatment.

EP. 7: Exciting Developments in the HER2+ Breast Cancer Treatment Landscape

May 18th 2022

Sarah M. Tolaney, MD, MPH, highlights recent and investigative treatments for HER2+ breast cancer that excite her and provides some clinical pearls for community oncologists.